Skip to main
PSNL

Personalis Inc (PSNL) Stock Forecast & Price Target

Personalis Inc (PSNL) Analyst Ratings

Based on 6 analyst ratings
Buy
Strong Buy 67%
Buy 0%
Hold 33%
Sell 0%
Strong Sell 0%

Bulls say

Personalis is positioned for strong biopharma revenue growth with the adoption of its ImmunoID NeXT platform, Medicare reimbursement wins, and a large addressable MRD market of ~$20 billion. The recent acquisition offer from TEM at a significant premium to the current trading price further validates the potential of Personalis. However, the company's low margins and significant cash burn may lead to a discount in its valuation compared to its peers. Despite potential risks such as slower adoption and increased competition, Personalis' proven track record and strong partners make it an attractive investment opportunity.

Bears say

Personalis is expected to be acquired by Tempus AI in late 2026 or early 2027, which may not be priced at a substantial premium to Thursday's closing price of $15.58, potentially leading to a stagnant stock price and causing concerns about the validity of the deal. Additionally, the company faces execution and focus risks with its commercial partner, Tempus, and volatility in ordering patterns from pharma companies. With a bear case scenario projecting a price target of $6.00 per share, investors should exercise caution when considering investing in Personalis.

Personalis Inc (PSNL) has been analyzed by 6 analysts, with a consensus rating of Buy. 67% of analysts recommend a Strong Buy, 0% recommend Buy, 33% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Personalis Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Personalis Inc (PSNL) Forecast

Analysts have given Personalis Inc (PSNL) a Buy based on their latest research and market trends.

According to 6 analysts, Personalis Inc (PSNL) has a Buy consensus rating as of Sep 23, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $14.75, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $14.75, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Personalis Inc (PSNL)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.